Platin-C containing nanoparticles: a recipe for the delivery of curcumin–cisplatin combination chemotherapeutics to mitochondria

Abstract

The success story of cisplatin spans over six decades now and yet it continues to be the key player in most chemotherapeutic regimens. Numerous efforts have been made to improve...

Circumventing challenges in mitochondrial targeting for cancer treatment: leveraging nanoplatforms for effective solutions

“…This research contributes to the understanding of combining the effects of chemotherapy and inflammation through the use of the cisplatin prodrug approach. 130 The dataset presented in Table 2 provides a detailed overview of the different nanoplatforms that are currently being utilized for the targeting of mitochondria, with a focus on the specific moieties that are involved in this process.…”

Biotin and boron-dipyrromethene-tagged platinum(iv) prodrug for cellular imaging and mito-targeted photocytotoxicity in red light

“…SCE) at a scan rate of 100 mV s −1 . The irreversible nature of this process is due to the loss of two axial ligands from the sixcoordinate 5d 6 -Pt(IV) prodrug to generate a four-coordinate 5d 8 -Pt(II) species. The absence of any anodic counterpart of the cathodic peak at various scan rates indicated the presence of an electron transfer with the concomitant chemical transformation (EC) mechanism to be operative for this metalbased redox process.…”

“…[4][5][6] Pt(IV) prodrugs are attractive alternatives to their Pt (II) counterparts because these 6-coordinate prodrugs with a 5d 6 -electronic configuration are kinetically inert to ligand substitution reactions, thus minimizing any unwanted drug alteration. [7][8][9][10] Once the prodrug is internalized in the tumour cells, it becomes activated by external or internal stimuli that include cellular reductants enriched in cancer cells, such as ascorbic acid, and glutathione, or through activation by light irradiation with the appropriate wavelength. Two axially attached ligands in the Pt(IV) core provide the means to augment its pharmacological properties to overcome any drug resistance.…”

Epithelial Ovarian Cancer: A Five Year Review

“…In the study by Banik B. et al [ 39 ], it was reported that mitochondria are used as a target for cisplatin. Ovarian cancer cells are sensitive to cisplatin.…”